A new set of community-produced biological network models has been shown to allow a deeper understanding of the mechanisms underlying a range of diseases.
Takeda and Theravance Biopharma, Inc. announced that the companies have entered into a global license, development and commercialization agreement for TD-8954, a selective 5-HT4 receptor agonist being investigated for potential use in the treatment of gastrointestinal motility disorders, including enteral feeding intolerance (“EFI”).
Amgen announced that The Lancet published results from a Phase 3 randomized, double-blind, placebo-controlled study of Nplate in children with symptomatic immune thrombocytopenia.
GSK presented new data for its meningococcal group B vaccine, Bexsero®,1 [Meningococcal group B Vaccine (rDNA, component, adsorbed)] comparing safety and immunogenicity with different dosing schedules in infants and young children, at the annual meeting of the European Society for Paediatric Infectious Diseases (ESPID).
FIrst PCSK9 Inhibitor in Japan,Providing A new TREATMENT option for certain patients who have high risk in cardiovascular events and do not adequately respond to statins.